Long-Term Treatment With Imidapril but Not With Nifedipine Enhances Plasma NOx Concentration in Patients With Essential Hypertension

この論文にアクセスする

この論文をさがす

著者

    • Suda Osamu SUDA Osamu
    • Second Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
    • HORIUCHI Masataka
    • Second Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
    • NAKATA Sei
    • Second Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
    • KOUZUMA Ryouji
    • Second Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
    • OKAZAKI Masahiro
    • Second Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
    • YANAGIHARA Nobuyuki
    • Department of Pharmacology, School of Medicine, University of Occupational and Environmental Health
    • TASAKI Hiromi
    • Second Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
    • NAKASHIMA Yasuhide
    • Second Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health

抄録

We investigated whether long-term treatment with the angiotensin-converting enzyme (ACE) inhibitor imidapril or the calcium channel antagonist nifedipine increases systemic nitric oxide (NO) production in patients with essential hypertension. Twenty-nine patients with essential hypertension were randomly divided into two groups, and they were treated with either imidapril or nifedipine once daily p.o. for 4 weeks. Long-term treatment with imidapril significantly decreased blood pressure and increased plasma NOx concentration. Long-term treatment with nifedipine also caused a comparable extent of significant decrease in blood pressure, but failed to alter plasma NOx levels. The imidapril treatment significantly inhibited serum ACE activity and increased plasma bradykinin concentration. Furthermore, the extent of inhibition of serum ACE activity and the extent of increase in plasma bradykinin concentration in response to the imidapril treatment were both significantly correlated with the extent of increase in plasma NOx concentration. In contrast, no such changes were noted after the nifedipine treatment. These results provide the first evidence that long-term treatment with imidapril enhances plasma NOx concentration in patients with essential hypertension. This effect does not seem to be due to the decrease in blood pressure. The increase in bradykinin concentration may be involved in the enhancing effect of the ACE inhibitor on NOx production in vivo.<br>

収録刊行物

  • Journal of pharmacological sciences  

    Journal of pharmacological sciences 101(2), 159-165, 2006-06-20 

    The Japanese Pharmacological Society

参考文献:  42件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10018237838
  • NII書誌ID(NCID)
    AA11806667
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    13478613
  • NDL 記事登録ID
    7963365
  • NDL 雑誌分類
    ZS51(科学技術--薬学)
  • NDL 請求記号
    Z53-D199
  • データ提供元
    CJP書誌  NDL  J-STAGE 
ページトップへ